Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients

Analysis of the Efficacy and Tolerance of Covid-19 Convalescent Plasma and Monoclonal Antibodies in the Treatment of SARS-Cov2 Infections in Immunocompromised Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05905380

Acronym

Covid-IC

Enrollment

200

Registered

2023-06-15

Start date

2023-03-02

Completion date

2024-01-31

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Convalescent Plasma Treatment

Keywords

Covid-19, SARS-Cov2, Immunosuppression, Cytokine, Convalescent Plasma, Monoclonal, Antibodies

Brief summary

Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more selected patients , in particular immunocompromised patients suggest a benefit in these patients whose clinical manifestation seems essentially related to the uncontrolled infection and not the cytokine storm.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Adult patient * Immunocompromised patient (solid neoplasia, malignant hemopathy, solid organ transplantation, primary immune deficiency, systemic disease, chronic inflammatory disease, etc.) * Hospitalized between 25/02/2020 and 15/01/2023 at HUS, ICANS, CH Colmar and CH Mulhouse * Having received curative monoclonal antibody treatment or convalescent plasma treatment for SARS-Cov2 infection * Patient who has not expressed, after being informed, his opposition to the reuse of his data for scientific research purposes.

Exclusion criteria

* Subject who expressed their opposition to participating in the study * Subject under guardianship, curatorship or safeguard of justice

Design outcomes

Primary

Measure	Time frame	Description
Retrospective analysis of the tolerance of Covid-19 convalescent plasma and monoclonal antibodies in the treatment of SARS-Cov2 infections in immunocompromised patients	Files analysed retrospectively from February 25, 2020 to January 15, 2023 will be examined	This is a retrospective study on patient data from medical records from February 25, 2020 to January 15, 2023

Countries

France

Contacts

Primary ContactFrançois DANION, MD

Francois.danion@chru-strasbourg.fr33 3 69 55 15 88

Outcome results